Drug Patents owned by Galderma Labs Lp

1. Drug name - AKLIEF

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7807708 GALDERMA LABS LP Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof
Oct, 2026

(3 years from now)

CN101087752B GALDERMA LABS LP New Ligand Of Adjusting Rar Receptor And Use Thereof In Human Medicine And Cosmetics
Dec, 2025

(3 years from now)

CN101087752A GALDERMA LABS LP New Ligand Of Adjusting Rar Receptor And The Usage In The Human Medicine And Makeup Thereof
Dec, 2025

(3 years from now)

IN200705201P1 GALDERMA LABS LP Novel Ligands That Modulate Rar Receptors And Use Thereof Inhuman Medicine And In Cosmetics
Dec, 2025

(3 years from now)

IN284413B GALDERMA LABS LP Novel Ligands That Modulate Rar Receptors And Use Thereof In Human Medicine And In Cosmetics
Dec, 2025

(3 years from now)

EP1831149B1 GALDERMA LABS LP Novel Ligands That Modulate Rar Receptors And Use Thereof In Human Medicine And In Cosmetics
Dec, 2025

(3 years from now)

EP1831149A1 GALDERMA LABS LP Novel Ligands That Modulate Rar Receptors And Use Thereof In Human Medicine And In Cosmetics
Dec, 2025

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8227507 GALDERMA LABS LP Ligands that modulate RAR receptors Dec, 2025

(3 years from now)

US8470871 GALDERMA LABS LP Ligands that modulate RAR receptors Dec, 2025

(3 years from now)

US9084778 GALDERMA LABS LP Topical compositions containing a retinoid of the oil-in-water emulsion type May, 2033

(10 years from now)

US9498465 GALDERMA LABS LP Topical compositions in the form of a gel containing a particular solubilized retinoid May, 2033

(10 years from now)

Drugs and Companies using TRIFAROTENE ingredient

Treatment: Topical treatment of acne vulgaris; Method of activating rargamma receptor; Treatment of acne vulgaris

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.005% CREAM;TOPICAL Prescription

2. Drug name - DIFFERIN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7834060 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US8703820 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US7838558 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Mar, 2023

(5 months from now)

US7868044 GALDERMA LABS LP Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid Mar, 2023

(5 months from now)

US7737181 GALDERMA LABS LP Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Aug, 2024

(1 year, 10 months from now)

US7579377 GALDERMA LABS LP Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders Feb, 2025

(2 years from now)

US8435502 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers Sep, 2026

(3 years from now)

US8709392 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers Sep, 2026

(3 years from now)

US7998467 GALDERMA LABS LP Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers May, 2028

(5 years from now)

Drugs and Companies using ADAPALENE ingredient

Treatment: Treatment of acne; Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.3% GEL;TOPICAL Prescription

3. Drug name - EPIDUO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8809305 GALDERMA LABS LP Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris Dec, 2022

(2 months from now)

US8105618 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide Dec, 2022

(2 months from now)

US8936800 GALDERMA LABS LP Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Dec, 2022

(2 months from now)

US8241649 GALDERMA LABS LP Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide Dec, 2022

(2 months from now)

US7964202 GALDERMA LABS LP Method for treatment of common acne Sep, 2024

(1 year, 10 months from now)

US7820186 GALDERMA LABS LP Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt Nov, 2025

(3 years from now)

US8445543 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

US8071644 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

US8080537 GALDERMA LABS LP Combinations of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

US8129362 GALDERMA LABS LP Combination/association of adapalene and benzoyl peroxide for treating acne lesions Jul, 2027

(4 years from now)

Drugs and Companies using ADAPALENE; BENZOYL PEROXIDE ingredient

Treatment: Treatment of acne

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.1%;2.5% GEL;TOPICAL Prescription

4. Drug name - MIRVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May, 2024

(1 year, 7 months from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May, 2025

(2 years from now)

US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis May, 2025

(2 years from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema May, 2025

(2 years from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea Aug, 2025

(2 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use Jun, 2031

(8 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use Jun, 2031

(8 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition Jun, 2031

(8 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 0.33% BASE GEL;TOPICAL Prescription

5. Drug name - ORACEA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8709478 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8394406 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8394405 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8470364 GALDERMA LABS LP Once daily formulations of tetracyclines Apr, 2024

(1 year, 6 months from now)

US8206740 GALDERMA LABS LP Once daily formulations of tetracyclines Dec, 2025

(3 years from now)

US7749532 GALDERMA LABS LP Once daily formulations of tetracyclines Dec, 2027

(5 years from now)

Drugs and Companies using DOXYCYCLINE ingredient

Treatment: Treatment of only inflammatory lesions (papules and pustules) of rosacea

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
40MG CAPSULE;ORAL Prescription

6. Drug name - SOOLANTRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8415311 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US8080530 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US11033565 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US8470788 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US7550440 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US8815816 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US8093219 GALDERMA LABS LP Topical application of ivermectin for the treatment of dermatological conditions/afflictions Apr, 2024

(1 year, 6 months from now)

US9782425 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

US9233117 GALDERMA LABS LP Treatment of inflammatory lesions of rosacea with ivermectin Mar, 2034

(11 years from now)

US9089587 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

US9233118 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

US10206939 GALDERMA LABS LP Treatment of papulopustular rosacea with ivermectin Mar, 2034

(11 years from now)

Drugs and Companies using IVERMECTIN ingredient

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

7. Drug name - TRI-LUMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8247395 GALDERMA LABS LP Topical skin care composition Oct, 2022

(20 days from now)

US8653053 GALDERMA LABS LP Topical skin care composition Oct, 2022

(20 days from now)

US7939516 GALDERMA LABS LP Topical skin care composition Sep, 2023

(11 months from now)

US7915243 GALDERMA LABS LP Topical skin care composition Sep, 2023

(11 months from now)

More Information on Dosage
Strength Dosage Availability
0.01%;4%;0.05% CREAM;TOPICAL Prescription

8. Drug name - TWYNEO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617580 GALDERMA LABS LP Compositions for topical application comprising a peroxide and retinoid Feb, 2028

(5 years from now)

US9868103 GALDERMA LABS LP Metal oxide coating of water insoluble ingredients Aug, 2028

(5 years from now)

US11071878 GALDERMA LABS LP Core stabilized microcapsules, method of their preparation and uses thereof Dec, 2030

(8 years from now)

US10653899 GALDERMA LABS LP Core stabilized microcapsules, method of their preparation and uses thereof Dec, 2030

(8 years from now)

US10420743 GALDERMA LABS LP Methods and compositions for the treatment of acne Jul, 2038

(15 years from now)

Drugs and Companies using BENZOYL PEROXIDE; TRETINOIN ingredient

Treatment: Topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
3%;0.1% CREAM;TOPICAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.